Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15082923 | 0.88 | MAPT (0.61) | KAT2BTSHRCYP3A4MAPTTDP1 | |
| SCHEMBL18477376 | 0.83 | MAPT (0.50) | KAT2BMAPTTDP1L3MBTL1MAPK1 | |
| SCHEMBL8655505 | 0.82 | KAT2B (0.56) | KAT2BTSHRCYP3A4MAPTTDP1 | |
| SCHEMBL6250970 | 0.82 | KAT2B (0.66) | KAT2BTSHRCYP3A4MAPTTDP1 | |
| SCHEMBL4640284 | 0.81 | KAT2B (0.64) | KAT2BTSHRCYP3A4MAPTTDP1 | |
| SCHEMBL7072960 | 0.81 | MEN1 (0.53) | MAPTTDP1L3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL3440916 | 0.80 | HCAR3 (0.57) | MAPTL3MBTL1ALDH1A1HTTNPC1 | |
| SCHEMBL117698 | 0.80 | KMT2A (0.66) | CYP3A4MAPTMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL18680085 | 0.80 | KAT2B (0.56) | KAT2BTSHRCYP3A4MAPTTDP1 | |
| SCHEMBL10249409 | 0.79 | KAT2B (0.71) | KAT2BTSHRCYP3A4MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | KAT2B 1631/4885TSHR 396/4885CYP3A4 285/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | KAT2B 1631/4885TSHR 396/4885CYP3A4 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.